Skip to main content
Recruiting Clinical Trials

Study of Cytoreductive Surgery and Hyperthermic Intraoperative Chemotherapy With Pemetrexed and Cisplatin for Malignant Pleural Mesotheliomas

By April 24, 2017No Comments

Condition

Mesothelioma

Estimated Enrollment: 36

Age Group: 18 Years to 80 Years   (Adult, Senior)

Gender: All

Study Type: Interventional

Study Design Allocation: Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Other

Study ID Numbers: H-36460

Study First Received: July 16, 2016

Last Updated: March 24, 2017

Estimated Primary Completion Date: July 2018

 

Primary Outcome Measures:

Safety Maximum Tolerated Dose of HIOC with cisplatin and pemetrexed for Malignant Pleural Mesothelioma.

Sponsors and Collaborators:

Baylor College of Medicine

Website Link: https://ClinicalTrials.gov/show/NCT02838745

Leave a Reply